One interview is better than thousand words… ReWalk Robotics Ltd.3 Hatnufa Street6th FloorYokne’am Illit 2069203Israelhttp://www.rewalk.com
ReWalk Robotics (RWLK): Yesterday, Today and Tomorrow
ADMA Biologics, Inc. (ADMA): Offering is Imminent
ADMA Biologics, Inc. (ADMA) shares price almost doubled since company announced that the FDA approved its Asceniv, intravenous immunoglobulin product for the treatment of primary humoral immunodeficiency disease (PIDD), in adults and adolescents ages from 12 to 17. PIDD is a collective term for numerous diseases that occur due to defects in the body’s immune …Read More
Sientra (NASDAQ: SIEN) : DD and More
A few excerpts: PennyStockHaven: From Sientra’s (SIEN) 8-K filing from October 30th, 2015: We continue to be well funded with a cash and cash equivalents balance of $148.9 million as of September 30, 2015. Earlier this week we paid in full our term loans totaling $24.5 million, and as a result the company has no outstanding …Read More
SANUWAVE (SNWV): U.S. Patent to Sterilize Blood Using SNWV’s Shock Wave Technology
SANUWAVE Health, Inc. (OTCBB:SNWV) has received a patent issued by the U.S. Patent and Trademark Office entitled “Method and Devices for Cleaning and Sterilization with Shock Waves.” The claims of the patent (patent number 8,343,420) relate to a new method that sterilizes blood by applying external shock waves to destroy blood pathogens contained in bags, …Read More
AntriaBio (ANTB): An Opportunity
Novo Nordisk – the world’s largest insulin producer – and major diabetes drug manufacturers – could see BILLIONS in recurring revenue dry up as a small, California-based biotech company advances a technology that promises to change diabetes treatment. Over $100,000,000 has been invested in developing this super-drug that threatens to make products like Sanofi’s $6 …Read More
Celsion (CLSN): Cash and Incentives up to $100 Million
Celsion (NASDAQ: CLSN) is developing a ThermoDox, a treatment for primary liver cancer. The company combines radio-frequency thermal ablation (RFA) with a high dose of the drug doxorubin. ThermoDox targets a specific area and then cover the tumor through the process of heating the accumulated drug. Phase III results show that ThermoDox with RFA treatment improves the …Read More
Protalix BioTherapeutics (PLX): Offer of Potential All-Cash Acquisition
Protalix BioTherapeutics, Inc. (PLX) is a biopharmaceutical company that is revolutionizing the development and manufacturing of recombinant therapeutic proteins through its ProCellEx® plant cell-based protein expression system. Using ProCellEx, Protalix is focused on the development and commercialization of a proprietary pipeline of novel and biosimilar proteins that target large, established pharmaceutical markets and that rely …Read More
Exelixis, Inc. (NASDAQ: EXEL): COMETRIQ Availability in the U.S.
Exelixis, Inc. (NASDAQ: EXEL) is a biopharmaceutical company committed to developing and commercializing small molecule therapies for the treatment of cancer. Exelixis announced on Thursday the commercial availability of COMETRIQ® (cabozantinib) for the treatment of patients with progressive, metastatic medullary thyroid cancer approved by FDA on November 29, 2012. COMETRIQ (cabozantinib) is being distributed exclusively …Read More
Neuralstem (CUR): FDA Approval for the Phase 1 Trial of NSI-566
Neuralstem’s (CUR) patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. In August 2012, Neuralstem completed the final surgery of an FDA-approved Phase I NSI-566 …Read More
iBio, Inc. (IBIO): Speculative Flu Vaccine Stock
Sophisticated traders must take a look at iBio, Inc. (IBIO) as it seems that company has been overlooked as a solid player on the flu market. The high level of flu cases being reported across all states in the USA and Europe. Only in New York state a flu epidemic has hit more than 19,000 …Read More